Compare IX & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IX | BDX |
|---|---|---|
| Founded | 1950 | 1897 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 43.0B |
| IPO Year | 1999 | 1998 |
| Metric | IX | BDX |
|---|---|---|
| Price | $40.07 | $177.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $186.00 |
| AVG Volume (30 Days) | 277.3K | ★ 1.5M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | 2.33% | ★ 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.59 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $12.73 | N/A |
| Revenue Next Year | $4.32 | $3.02 |
| P/E Ratio | ★ $12.93 | $113.08 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $24.19 | $140.11 |
| 52 Week High | $42.39 | $213.08 |
| Indicator | IX | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 41.37 |
| Support Level | $37.78 | $153.27 |
| Resistance Level | $40.16 | $192.41 |
| Average True Range (ATR) | 0.51 | 3.72 |
| MACD | -0.01 | -2.42 |
| Stochastic Oscillator | 28.58 | 0.52 |
ORIX Corp is a diversified financial services company with operations in Corporate Financial Services, Maintenance Leasing, Real Estate, PE Investment and Concession, Environment and Energy, Insurance, Banking and Credit, Aircraft and Ships, ORIX USA, ORIX Europe, Asia, and Australia and engages in various other fee businesses by providing products and services aligned with customer needs to its core customer base of domestic small and medium-sized enterprises. Orix's numerous divisions finance leases of large-ticket items like ships, airplanes, and technology equipment. The company generates the majority of its revenue from Corporate Financial Services and Maintenance Leasing operations and Real Estate operations.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.